Aytu Biopharma (AYTU) Proxy filing summary

Executive summary

• Annual meeting scheduled for Dec. 10, 2026, at 10:00 a.m. Mountain time, in person in Denver; voting deadline is Dec. 9, 2026, at 11:59 p.m. Eastern time.

• Board recommends voting for all five listed proposals, including director nominees, equity plans, auditor ratification, and the advisory executive compensation vote.

Voting matters and shareholder proposals

• Director nominees: Joshua R. Disbrow, John A. Donofrio, Jr., Carl C. Dockery, Abhinav “Abi” Jain, and Vivian H. Liu; Board recommends for each.

• Board recommends approval of Amendment No. 2 to the 2023 Equity Incentive Plan, adding 500,000 reserved shares and bringing the total to 1,000,000, excluding certain prior-plan and returned shares.

• Board recommends approval of the 2027 Employee Stock Purchase Plan.

• Board recommends ratifying Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending June 30, 2027.

• Board recommends approval of the advisory vote on executive compensation.

Board of directors and corporate governance

• Five director nominees are up for election: Joshua R. Disbrow, John A. Donofrio, Jr., Carl C. Dockery, Abhinav “Abi” Jain, and Vivian H. Liu.